Categorie: IPO / Secondary Offering
Submitted about 1 year ago by
Felicia
, Small Investor
at Self Employed
Broncus Technologies Inc. - IPO (NASDAQ (GM): LUNG Proposed) A good stock to own Why? Because there's no company with a commercial solution to treat emphysema. Let me start with the industry overview to get a fair idea of how well Broncus Technologies is positioned to move from strength to strength. National Center for Health Statistics found that 3.8 million adults were diagnosed with emphysema and many more still undiagnosed. Emphysema is responsible for $5 billion in direct health care costs. National Emphysema Treatment Trial study says $20,000 per patient is the cost for treatment. This particular study was co-sponsored by the National Institutes of Health. Emphysema develops due to chronic smoking and the characteristics of the diseases are difficult breathing and shortness of breath. The World Health Organization estimated 1.3 billion smokers worldwide. United States is the home for 45 million smokers. Currently there's no cure for this disease. Patients are encouraged to stop smoking to slow disease progression and in severe cases are prescribed supplemental oxygen. Broncus has patented its Airway Bypass treatment method and uses Exhale emphysema product line to perform the bypass treatment. Airway Bypass is a catheter-based bronchoscopic procedure and helps the patients to breath easy. Typically air...
More...
Submitted about 1 year ago by
Felicia
, Small Investor
at Self Employed
0 comments ↓